Anti-TNFα binding compounds and uses thereof
AssigneeFull Spectrum Genetics, Inc.
InventorsRobert DuBridge, Veronica Juan
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel Anti-TNFα antibody binding compounds and methods of using the same. Anti-TNFα antibody binding compounds of the invention comprise novel heavy chain immunoglobulin polypeptides of portions thereof. In some embodiments, the invention also includes pharmaceutical compositions comprising at least one Anti-TNFα antibody binding compound. The invention further provides the use of an Anti-TNFα antibody binding compound of the invention in the preparation of a medicament for the therapeutic and/or prophylactic treatment of a disorder.
Claims3
An isolated antibody binding compound specific for the human TNFα comprising heavy chain and light chain complementary determining regions (CDRs) defined by the following amino acid sequences:
- heavy chain CDR1 (“HC1”):
- SEQ ID NO:
- 9;
- heavy chain CDR2 (“HC2”):
- SEQ ID NO:
- 39:
- heavy chain CDR3 (“HC3”):
- SEQ ID NO:
- 11;
- light chain CDR1 (“LC1”):
- SEQ ID NO:
- 40;
- light chain CDR2 (“LC2”):
- SEQ ID NO:
- 13;
- light chain CDR3 (“LC3”):
- SEQ ID NO:
- 14;
- wherein the antibody binding compound comprises framework residues f1, f2, f3 and f4 such that the heavy chain thereof is defined by the formula:
- f1-HC1-f2-HC2-f3-HC3-f4, and such that said heavy chain is at least 80 percent identical to SEQ ID NO:
- 7;
- wherein antibody binding compound comprises framework residues g1, g2, g3 and g4 such that the light chain thereof is defined by the formula:
- g1-LC1-g2-LC2-g3-LC3-g4, and such that said light chain is at least 80 percent identical to SEQ ID NO:8;
- and
- wherein the isolated antibody binding compound has an affinity for human TNFα that is characterized by an equilibrium binding constant of 100 nM or less.
Dependencies are inferred from the claim text.